| 摘要: |
| ［摘要］ 目的 分析急性髓系白血病（AML）患儿骨髓酸性核磷蛋白32家族成员B（ANP32B）、RAS致癌基因家族成员10（RAB10）的表达水平及其与临床特征、生存预后的关联性。方法 招募2019年3月至2021年3月山西省儿童医院收治的96例AML患儿作为AML组。另选取同期50例因检查其他疾病而做骨髓穿刺排除恶性血液病的儿童作为对照组。采用定量聚合酶链反应（qPCR）法检测骨髓ANP32B、RAB10水平。于第一疗程结束后评估疗效。记录3年随访期间AML患儿的生存情况，采用Cox回归分析AML患儿生存预后的影响因素。结果 AML组ANP32B水平显著高于对照组［（3.12±0.43） vs （1.05±0.22），t=31.898，P<0.001］，AML组RAB10水平显著高于对照组［（2.85±0.37） vs （0.95±0.21），t=33.569，P<0.001］。第一疗程未完全缓解、危险度分层为高危的AML患儿ANP32B、RAB10水平显著升高（P<0.05）。患儿随访时间为4～36（28.21±4.16）个月，3年总生存率为66.67%。ANP32B低表达组（≤3.12，50例）的生存预后显著优于ANP32B高表达组（>3.12，46例）（log-rank检验： χ2=9.420，P=0.001）；RAB10低表达组（≤2.85，49例）的生存预后显著优于RAB10高表达组（>2.85，47例）（log-rank检验： χ2=19.720，P<0.001）；ANP32B+RAB10共低表达组的生存预后显著优于ANP32B+RAB10共高表达组（log-rank检验：χ2=56.590，P<0.001）。多因素Cox回归分析结果显示，危险度分层为高危、第一疗程未完全缓解、ANP32B高表达、RAB10高表达是AML患儿发生死亡的独立危险因素（P<0.05）。结论 AML患儿骨髓ANP32B、RAB10水平升高，其水平与危险度分层、第一疗程是否完全缓解以及生存预后有关。 |
| 关键词: 急性髓系白血病 儿童 酸性核磷蛋白32家族成员B RAS致癌基因家族成员10 生存预后 |
| DOI：10.3969/j.issn.1674-3806.2025.08.10 |
| 分类号:R 733.71 |
| 基金项目:山西省卫生健康科研课题（编号：2020106）；山西省基础研究计划项目（编号：202103021223448） |
|
| Expressions of ANP32B and RAB10 in bone marrow of pediatric patients with acute myeloid leukemia and their relationship with clinical characteristics and survival prognosis |
|
HE Minhui1, YANG Chao2, ZHANG Xiaodong2, ZHANG Xianhui3
|
|
1.Clinical Laboratory Center, Shanxi Children′s Hospital(Shanxi Women and Children Hospital), Taiyuan 030000, China; 2.Department of Clinical Laboratory, Taiyuan Central Hospital, Taiyuan 030009, China; 3.Department of Adult Internal Medicine, Shanxi Children′s Hospital(Shanxi Women and Children Hospital), Taiyuan 030000, China
|
| Abstract: |
| ［Abstract］ Objective To analyze the expressions of acidic leucine-rich nuclear phosphoprotein 32 family member B(ANP32B) and RAS oncogene family member 10(RAB10) in bone marrow of pediatric patients with acute myeloid leukemia(AML) and their relationship with clinical characteristics and survival prognosis. Methods A total of 96 pediatric patients with AML who were admitted to Shanxi Children′s Hospital from March 2019 to March 2021 were recruited as AML group. Other 50 children who underwent bone marrow puncture for the examination of other diseases during the same period and were excluded from malignant hematological diseases were selected as control group. The levels of ANP32B and RAB10 in bone marrow were detected by using quantitative polymerase chain reaction(qPCR). The therapeutic effect was evaluated after the end of the first course of treatment. The survival prognosis of the pediatric patients with AML during the 3-year follow-up period was recorded. Cox regression was used to analyze the influencing factors of survival prognosis in the pediatric patients with AML. Results The ANP32B level in the AML group was significantly higher than that in the control group［(3.12±0.43) vs (1.05±0.22), t=31.898, P<0.001］, and the RAB10 level in the AML group was significantly higher than that in the control group［(2.85±0.37) vs (0.95±0.21), t=33.569, P<0.001］. The levels of ANP32B and RAB10 in the pediatric patients with AML who did not achieve complete remission in the first course of treatment and were stratified as high risk were significantly increased(P<0.05). The follow-up time of the pediatric patients was 4-36(28.21±4.16)months, and their 3-year overall survival rate was 66.67%. The survival prognosis of the ANP32B low-expression group(≤3.12, 50 cases) was significantly better than that of the ANP32B high-expression group(>3.12, 46 cases)(log-rank test: χ2=9.420, P=0.001). The survival prognosis of the RAB10 low-expression group(≤2.85, 49 cases) was significantly better than that of the RAB10 high-expression group(>2.85, 47 cases)(log-rank test: χ2=19.720, P<0.001). The survival prognosis of the ANP32B+RAB10 low co-expression group was significantly better than that of the ANP32B+RAB10 high co-expression group(log-rank test: χ2=56.590, P<0.001). The results of multivariate Cox regression analysis showed that risk stratification as high risk, non-complete remission in the first course of treatment, high expression of ANP32B, and high expression of RAB10 were independent risk factors for death in the pediatric patients with AML(P<0.05). Conclusion The levels of ANP32B and RAB10 in the bone marrow of pediatric patients with AML are elevated, and the levels are related to risk stratification, whether there is complete remission in the first course of treatment, and survival prognosis. |
| Key words: Acute myeloid leukemia(AML) Children Acidic leucine-rich nuclear phosphoprotein 32 family member B(ANP32B) RAS oncogene family member 10(RAB10) Survival prognosis |
